BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leeson PD, Bento AP, Gaulton A, Hersey A, Manners EJ, Radoux CJ, Leach AR. Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies. J Med Chem 2021;64:7210-30. [PMID: 33983732 DOI: 10.1021/acs.jmedchem.1c00416] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Zhang T, Zhang Y, Zhang Z, Wang Z, Zhang X, Hu S, Lu P, Guo S, Meng F. Discovery of 4-(phenoxymethyl)-1H-1,2,3-triazole derivatives as novel xanthine oxidase inhibitors. Bioorganic & Medicinal Chemistry Letters 2022. [DOI: 10.1016/j.bmcl.2022.128582] [Reference Citation Analysis]
2 Roskoski R. Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106156] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Willis NJ, Mahy W, Sipthorp J, Zhao Y, Woodward HL, Atkinson BN, Bayle ED, Svensson F, Frew S, Jeganathan F, Monaghan A, Benvegnù S, Jolly S, Vecchia L, Ruza RR, Kjær S, Howell S, Snijders AP, Bictash M, Salinas PC, Vincent JP, Jones EY, Whiting P, Fish PV. Design of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit. J Med Chem 2022. [PMID: 35536179 DOI: 10.1021/acs.jmedchem.2c00162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Roskoski R Jr. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Pharmacol Res 2022;183:106362. [PMID: 35878738 DOI: 10.1016/j.phrs.2022.106362] [Reference Citation Analysis]
5 de Oliveira RG, Cruz LR, Mollo MC, Dias LC, Kratz JM. Chagas Disease Drug Discovery in Latin America-A Mini Review of Antiparasitic Agents Explored Between 2010 and 2021. Front Chem 2021;9:771143. [PMID: 34778217 DOI: 10.3389/fchem.2021.771143] [Reference Citation Analysis]
6 Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacol Res 2021;175:106037. [PMID: 34921994 DOI: 10.1016/j.phrs.2021.106037] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 27.0] [Reference Citation Analysis]
7 Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F, Qiu Y, Chen Y. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res 2021:gkab953. [PMID: 34718717 DOI: 10.1093/nar/gkab953] [Reference Citation Analysis]
8 Panda SS, Tran QL, Rajpurohit P, Pillai GG, Thomas SJ, Bridges AE, Capito JE, Thangaraju M, Lokeshwar BL. Design, Synthesis, and Molecular Docking Studies of Curcumin Hybrid Conjugates as Potential Therapeutics for Breast Cancer. Pharmaceuticals 2022;15:451. [DOI: 10.3390/ph15040451] [Reference Citation Analysis]